Sponsored by the Arizona State University Center for Evolution and Medicine In collaboration with the ASU Biosocial Complexity Initiative Live streaming link at the CEM Website on the symposium day This free symposium brings together experts from evolutionary biology, medicine, physiology, genetics, engineering, and complex systems to develop strategies for testing hypotheses about why natural selection has left physiological control systems vulnerable to failures that cause diseases such as cancer, autoimmune diseases, obesity, and emotional disorders.
Learn more and register (registration required only for on site attendees)
Thursday February 2, at noon (AZ time zone)
Keynote: The State of Detection Theory Pete Trimmer, NSF-Funded Postdoctoral Researcher University of California, Davis Winner of the 2016 George C. Williams Prize for the best paper in Evolution, Medicine & Public Health
Friday, February 3 Symposium 8:30-12:00 (Phoenix, AZ time zone)
8:30am Randolph M. Nesse (ASU Life Sciences) Fitness cliffs and vicious cycles: Evolutionary explanations for vulnerable control systems 8:50am Fred Nijhout (Duke University) Homeostatic mechanisms enable the persistence and accumulation of deleterious genes 9:10am Carl Carlson (Carlson Reliability Consulting) Using Failure Mode and Effects Analysis to advance evolutionary biology research and application 9:30am Jay Schulkin (University of Washington Medical School) Obesity: Biology and Culture 9:50am Athena Aktipis (ASU Psychology) The good, the bad and the arms race: How cooperation, competition and escalating conflict shape human health and disease 10:30am Ken Buetow (ASU Life Sciences) Complex human disease phenotypes as emergent properties of network variability 10:50am Manfred Laubichler (ASU Life Sciences) Stability vs. Vulnerability: The evolutionary conundrum 11:10am Rustom Antia (Emory University) ”Design principles” for robust immune systems 11:30am Carl Bergstrom (University of Washington) A hygiene hypothesis for anxiety
Nominations are open now for the 2016 Omenn Prize, to be awarded at the 2017 ISEMPH Meeting in Groningen, Netherlands. The submission deadline is March 31, 2017
The International Society for Evolution, Medicine & Public Health invites nominations for the Omenn Prize of $5000 for the best article published in 2016 in any scientific journal on a topic related to evolution in the context of medicine and public health. It will be awarded in August 2017 at the ISEMPH Meeting in Groningen, Netherlands.
The prize, provided by the generosity of Gilbert S. Omenn, will be awarded to the first author of the winning article. Authors are encouraged to nominate their own articles, but nominations of articles by others are also welcome.
Nominations close March 31, 2017
Any relevant peer-reviewed article with a publication date of 2016 for the final version of the article is eligible, but the prize is intended for work that uses evolutionary principles to advance understanding of a disease or disease process. The prize committee will give priority to articles with implications for human health, but many basic science or theoretical articles have such implications.
The Prize Committee for this year is chaired by Grazyna Jasienska, and its members are James Bull and Antonis Rokas. Papers by committee members, their students and lab group members are not eligible, and articles by their co-authors or close associates are subject to special conditions. The winner will be invited to present a talk at the meeting of the International Society for Evolution and Medicine.
Learn more about submitting a nomination.
Four essays address the Hot Topic of Alzheimer’s Disease. Please contribute your comments at the end of each essay, or send your own essay to email@example.com.
On the 23rd November this year pharmaceutical giant Eli Lilly announced that the phase II early-intervention Alzheimer’s disease trial for a monoclonal antibody – solanezumab – designed to remove excess beta-amyloid protein from the brain, had failed. The news has caused another round of hand-wringing and head-scratching in the Alzheimer’s research community because it comes on the back of many trials, costing decades-worth of valuable time and billions of dollars, that has assumed the classical amyloid hypothesis will provide valuable targets for drug intervention. In the light of this recent failure Evmedreview presents a new HOT TOPIC feature of three consecutive posts commenting on this perplexing failure. The first, from Evmedreview associate editor Jeremy Taylor, discusses whether synapse loss is a better indicator of Alzheimer’s disease than amyloid and tau pathology and highlights the role of environmental factors and the immune system in AD etiology. The second, from Caleb Finch, makes the point that environmental factors have been far too overlooked in AD etiology and, in a typical example of blue sky (or should it be grey sky in this case) thinking, is the first article to highlight the role of smoke, smoking and atmospheric pollution. The third commentary, from Robert Moir, is based on his work over the last decade that shows beta-amyloid to be a potent brain-based antimicrobial with obvious repercussions for the caution with which we should approach clearing amyloid out of the brain, and for the possible role of microbial infection as the initial trigger for AD pathology.
The following links demonstrate the extent to which successive drug trial failures have promoted rounds of navel gazing within the AD research community.
The aim of this new Interest Group is to gather a network of SGIM members who share fascination with the view of health and illness through an evolutionary lens. Through this lens, the very nature of questions one can ask shifts from proximate “what” questions about mechanism and development in individuals to evolutionary “why” questions about selection forces and phylogenetic development. Medicine is based on biology and biology is based on evolution but medical education and research rarely taps into the elegance and power of evolutionary principles. Please email Mark Schwartz at firstname.lastname@example.org with your interest so we can hit the ground running at the Annual Meeting in Miami..
The Society of General Internal Medicine was founded in 1978 by a national group of academic general internists committed to promoting research and education aimed at improving health care for the whole patient. The organization has grown to nearly 3,000 members over three decades. Drawing upon their expertise and diverse experiences, our members are from the United States and eleven other countries, SGIM members have become leaders in the specialty of internal medicine. The Society is dedicated to insuring that all adults receive high quality health care in the 21st century. The broad expertise of our members in research, education, and clinical practice places SGIM and its members at the forefront of medicine.